Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 4,017 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 4,017 shares of the stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $40.01, for a total transaction of $160,720.17. Following the completion of the sale, the insider directly owned 87,715 shares in the company, valued at $3,509,477.15. This trade represents a 4.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Castle Biosciences Trading Up 2.9%

Shares of NASDAQ:CSTL traded up $1.17 on Thursday, hitting $42.15. 251,119 shares of the company’s stock were exchanged, compared to its average volume of 350,844. The business’s 50 day simple moving average is $38.86 and its two-hundred day simple moving average is $28.02. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.47 and a quick ratio of 6.31. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -93.67 and a beta of 1.06. Castle Biosciences, Inc. has a 12 month low of $14.59 and a 12 month high of $43.01.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.32. The company had revenue of $80.55 million during the quarter, compared to analyst estimates of $71.06 million. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.73%. Analysts anticipate that Castle Biosciences, Inc. will post 0.44 EPS for the current fiscal year.

Hedge Funds Weigh In On Castle Biosciences

A number of large investors have recently bought and sold shares of CSTL. Farther Finance Advisors LLC grew its holdings in Castle Biosciences by 139,100.0% in the third quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company’s stock valued at $32,000 after purchasing an additional 1,391 shares during the period. State of Alaska Department of Revenue purchased a new position in Castle Biosciences in the 3rd quarter valued at about $35,000. CWM LLC raised its holdings in shares of Castle Biosciences by 80.6% during the third quarter. CWM LLC now owns 1,911 shares of the company’s stock valued at $44,000 after acquiring an additional 853 shares during the last quarter. Jones Financial Companies Lllp lifted its position in shares of Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after acquiring an additional 2,648 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in shares of Castle Biosciences by 63.7% in the third quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock worth $57,000 after acquiring an additional 976 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on CSTL shares. Canaccord Genuity Group raised their target price on shares of Castle Biosciences from $37.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. Zacks Research downgraded shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a report on Friday, January 2nd. Lake Street Capital increased their target price on shares of Castle Biosciences from $35.00 to $52.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Weiss Ratings reissued a “sell (d)” rating on shares of Castle Biosciences in a research report on Monday, December 29th. Finally, Guggenheim boosted their target price on shares of Castle Biosciences from $30.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Castle Biosciences currently has an average rating of “Moderate Buy” and an average price target of $46.00.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.